What is semaglutide and how does it cause weight loss?

Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone GLP-1 to reduce appetite, slow gastric emptying, enhance glucose-dependent insulin secretion, and suppress glucagon. Clinical trials show 10–18%+ total body weight reduction over 68 weeks.

Is compounded semaglutide the same as Ozempic or Wegovy?

Compounded semaglutide contains the same active molecule as Ozempic and Wegovy, prepared by a licensed compounding pharmacy with B12. It is not an FDA-approved brand product but is prepared under state pharmacy board oversight and federal compounding regulations.

How long does it take to see results on semaglutide?

Appetite reduction and food noise suppression typically begin in weeks 2–4. Measurable weight loss begins at the 0.6–1.1mg/week dose range (weeks 4–12 of titration). The 10–18% weight reduction data comes from 68-week clinical trials.

Do I need a prescription for semaglutide?

Yes. Semaglutide is prescription-only. An async telehealth consultation with a licensed provider is included with your VitalRx order at no additional charge.

Semaglutide — Prescription GLP-1 Weight Loss, Physician-Supervised

Compounded Semaglutide/B12 for chronic weight management, glycemic control, and metabolic health. The same active ingredient as Ozempic and Wegovy — sourced from a licensed compounding pharmacy, prescribed by a licensed provider.

Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1 to regulate appetite, insulin secretion, gastric emptying, and glucose levels. It is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and has demonstrated 10–18%+ total body weight reduction in clinical trials. At VitalRx, semaglutide is offered as a compounded Semaglutide/B12 formulation through a structured titration protocol — physician-supervised, with an async telehealth consultation included. No waiting rooms. No prior authorization battles. A prescription and a protocol tailored to you.

See Pricing

FDA-approved active ingredient — compounded by licensed pharmacy

Prescription required — licensed physician oversight

Async telehealth consultation included

FedEx Standard Overnight — cold-chain shipped

32 states and D.C.

What Semaglutide Is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic analog of the incretin hormone GLP-1 that the gut naturally releases in response to food. By binding GLP-1 receptors in the brain, gut, and pancreas, semaglutide produces a coordinated set of metabolic effects: reduced appetite and food intake, slowed gastric emptying, enhanced insulin secretion in response to glucose, suppressed glucagon, and reduced hepatic glucose output. The cumulative effect is sustained caloric deficit without the constant conscious restriction that makes behavioral weight loss difficult to maintain. It was FDA-approved as Ozempic (2017) for type 2 diabetes and cardiovascular risk reduction, as Wegovy (2021) for chronic weight management in adults and adolescents, and as Rybelsus for oral T2D management. VitalRx offers compounded Semaglutide/B12 — the same active molecule with added Cyanocobalamin (B12) to support energy metabolism and neurological function during active weight loss.

FDA-Approved Indications (Brand Products)

Ozempic

Type 2 diabetes, cardiovascular risk reduction

Wegovy

Chronic weight management — adults and adolescents

Rybelsus

Oral semaglutide for type 2 diabetes

VitalRx offers compounded Semaglutide/B12, prepared by a licensed compounding pharmacy. Compounded semaglutide contains the same active ingredient as brand-name products. B12 (Cyanocobalamin) is added to support energy and neurological health during weight loss.

How Semaglutide Works

Semaglutide works through multiple coordinated mechanisms — not a single pathway. This is why its weight loss and metabolic effects are more durable than stimulant-class appetite suppressants.

GLP-1 Receptor Activation in the Brain — Appetite Reduction

GLP-1 receptors in the hypothalamus and brainstem regulate appetite and satiety signaling. Semaglutide activates these receptors centrally, reducing hunger signals and — importantly — reducing 'food noise': the intrusive preoccupation with food that makes caloric restriction cognitively exhausting. Many patients report that food simply becomes less interesting, rather than something they are actively resisting. This central appetite effect is one of the most clinically significant aspects of GLP-1 therapy and one of the most underreported.

Gastric Emptying Delay — Prolonged Satiety

Semaglutide slows gastric emptying — food moves through the stomach more slowly, extending the duration of physical fullness after meals. This mechanical satiety effect complements the central appetite suppression, producing a sustained reduction in caloric intake through two independent pathways simultaneously.

Glucose-Dependent Insulin Secretion

Semaglutide enhances insulin secretion from pancreatic beta cells — but only in response to elevated blood glucose. This glucose-dependent mechanism means insulin is released when blood sugar rises (after eating) and not when glucose is normal, significantly reducing the risk of hypoglycemia compared to older diabetes medications. Improved insulin secretion and sensitivity contribute to better glycemic control and the metabolic health benefits beyond weight loss.

Glucagon Suppression and Hepatic Glucose Reduction

Semaglutide suppresses glucagon secretion from pancreatic alpha cells — reducing the liver's glucose output. This contributes to lower fasting glucose, improved A1C, and the reduction in insulin resistance that makes semaglutide a meaningful intervention for patients with type 2 diabetes, prediabetes, and metabolic syndrome.

Cardiovascular and Hepatic Benefits

The SUSTAIN and STEP clinical programs demonstrated that semaglutide significantly reduces the risk of major cardiovascular events — the mechanism behind the Ozempic CV risk reduction approval. Clinical data also shows meaningful reduction in liver fat (NAFLD/NASH), making semaglutide one of the few weight loss medications with direct hepatic benefit evidence.

What Semaglutide Can Do

10–18%+ Total Body Weight Reduction

The STEP clinical program demonstrated 10–18%+ total body weight reduction at 68 weeks in patients with obesity or overweight with comorbidities. This represents meaningful, sustained weight loss — significantly greater than what most behavioral interventions achieve without pharmacological support.

Phase III RCT — STEP clinical program

Strong Appetite and Food Noise Suppression

Central GLP-1 receptor activation reduces both physiological hunger and the cognitive preoccupation with food ('food noise') that makes caloric restriction difficult to sustain. Patients commonly report that eating less feels natural rather than effortful.

Well-established — primary mechanism

Improved A1C and Insulin Sensitivity

Semaglutide reliably improves A1C and insulin sensitivity — benefits relevant to patients with type 2 diabetes, prediabetes, or insulin resistance independent of weight loss. The glycemic improvement often precedes significant weight loss.

Phase III RCT — primary T2D endpoint

Blood Sugar Stabilization

Glucose-dependent insulin secretion and glucagon suppression stabilize postprandial blood sugar spikes. Patients with significant glycemic variability — energy crashes after meals, afternoon fatigue, carbohydrate cravings — often notice improvement early in their protocol.

Well-established — established mechanism

Cardiovascular Risk Reduction

The SUSTAIN-6 trial demonstrated significant reduction in major adverse cardiovascular events (MACE) — the basis for the Ozempic cardiovascular risk reduction indication. Relevant for patients with elevated cardiovascular risk alongside metabolic disease.

Phase III RCT — SUSTAIN-6

Potential NAFLD/NASH Benefit

Clinical data shows semaglutide significantly reduces liver fat in patients with non-alcoholic fatty liver disease — an important secondary benefit for the metabolic population where NAFLD is common.

Clinical trial data — established benefit

Who Semaglutide Is For

Ideal Candidates

BMI ≥30, or ≥27 with weight-related comorbidities (T2D, hypertension, dyslipidemia, cardiovascular disease)
Type 2 diabetes patients requiring glycemic control alongside weight management
PCOS or insulin resistance — semaglutide addresses the hormonal and metabolic drivers of weight gain in these patients
Patients who have attempted diet and exercise without achieving or sustaining adequate results
Perimenopause or menopause-related metabolic changes — hormonal shifts that drive visceral fat accumulation and insulin resistance

Semaglutide should be avoided in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), or with severe gastrointestinal disease. Your VitalRx provider will review your full health history during your consultation.

Do Not Combine with Tirzepatide

Semaglutide and tirzepatide both act on GLP-1 receptors and should not be used simultaneously. Combining dual GLP-1 pathway stimulation significantly increases the risk of gastrointestinal side effects and is not clinically appropriate. If you are considering tirzepatide, that is a separate protocol evaluated independently.

Titration Protocol

Semaglutide is administered as a subcutaneous injection — 25 units (0.25mL) twice weekly. The dose is titrated progressively upward over the course of your protocol, allowing your body to adapt to the GLP-1 receptor activation and minimizing gastrointestinal side effects. Your VitalRx provider establishes your starting vial and titration schedule based on your health history, weight, and metabolic goals.

Step	Vial	Weekly Dose	Duration	Purpose
Starter	Semaglutide/B12 0.6mg/mL — 2mL	~0.3mg/week	4 weeks	Establishes GLP-1 tolerance. Minimizes GI adaptation side effects. Confirms early appetite response before dose escalation.
Low Dose	Semaglutide/B12 1.2mg/mL — 2mL	~0.6mg/week	4 weeks	First therapeutic dose range. Many patients begin noticing appetite suppression and food noise reduction at this level.
Mid-Low Dose	Semaglutide/B12 2.2mg/mL — 2mL	~1.1mg/week	4+ weeks	Established therapeutic range for many patients. Weight loss typically becomes measurable at this dose level.
Mid Dose	Semaglutide/B12 3.4mg/mL — 2mL	~1.7mg/week	4+ weeks	Advanced therapeutic dose. Typically reached after 8–12 weeks on protocol. Stronger appetite suppression and accelerated weight loss.
Full Dose	Semaglutide/B12 5.6mg/mL — 2mL	~2.8mg/week	Ongoing maintenance	Maximum dose range. Corresponds to the Wegovy 2.4mg/week clinical dose level. Reserved for patients who tolerated lower doses well and require continued dose optimization.

Starter

~0.3mg/week

Semaglutide/B12 0.6mg/mL — 2mL